Private Advisor Group LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 15,465 shares of the biopharmaceutical company’s stock, valued at approximately $226,000.

Other hedge funds have also modified their holdings of the company. Bank of Montreal Can increased its stake in Halozyme Therapeutics by 80.4% in the 4th quarter. Bank of Montreal Can now owns 2,011 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 896 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in Halozyme Therapeutics in the 3rd quarter valued at $123,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Halozyme Therapeutics by 33.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,791 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 2,430 shares during the last quarter. Verition Fund Management LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter valued at $182,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in Halozyme Therapeutics in the 3rd quarter valued at $205,000. Hedge funds and other institutional investors own 82.59% of the company’s stock.

Several brokerages have issued reports on HALO. JMP Securities reiterated a “buy” rating and issued a $21.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, February 27th. Cantor Fitzgerald reissued a “buy” rating and issued a $27.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, December 5th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Tuesday, January 15th. BidaskClub downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 8th. Finally, TheStreet downgraded shares of Halozyme Therapeutics from a “c” rating to a “d” rating in a research report on Tuesday, March 5th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $20.17.

Shares of HALO opened at $16.08 on Friday. Halozyme Therapeutics, Inc. has a one year low of $13.24 and a one year high of $21.48. The stock has a market capitalization of $2.33 billion, a PE ratio of -28.71 and a beta of 1.87. The company has a quick ratio of 2.71, a current ratio of 2.86 and a debt-to-equity ratio of 0.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, February 21st. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Halozyme Therapeutics had a negative net margin of 52.90% and a negative return on equity of 31.86%. The company had revenue of $60.23 million during the quarter, compared to the consensus estimate of $59.77 million. During the same quarter last year, the firm posted $0.85 EPS. The company’s quarterly revenue was down 68.2% on a year-over-year basis. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post -0.43 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/private-advisor-group-llc-purchases-new-position-in-halozyme-therapeutics-inc-halo/2895758.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Article: Current Ratio

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.